Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 375, Issue 2, 2007, Pages 95-103

  Fredersdorf, Sabine ^a   Weil, Joachim ^a,b   Ulucan, Coskun ^a   Birner, Christoph ^a   Büttner, Roland ^a   Schubert, Thomas ^c   Böger, Carsten A ^a   Debl, Kurt ^a   Muders, Frank ^a   Riegger, Günter A ^a   Luchner, Andreas ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Diabetes mellitus; Glomerulosclerosis; Kidney; Vasopeptidase inhibition

Indexed keywords

AVE 7688; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; RAMIPRIL; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL DAMAGE; CELL STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; HETEROZYGOSITY; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; HETEROCYCLIC COMPOUNDS, 3-RING; MALE; MICROSCOPY, POLARIZATION; NEPRILYSIN; PODOCYTES; PROTEASE INHIBITORS; PROTEINURIA; RAMIPRIL; RATS; RATS, ZUCKER; RENIN-ANGIOTENSIN SYSTEM; TRIGLYCERIDES; WEIGHT GAIN;

EID: 33947228321     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0147-9     Document Type: Article

References (40)

1. Appel RG (1990) Mechanism of atrial natriuretic factor-induced inhibition of rat mesangial cell mitogenesis. Am J Physiol 259:312-318
2. Böger CA, Götz A, Krüger B, Hösl M, Schmitz G, Riegger GAJ, Krämer BK (2005) Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors orangiotensin receptor blockers in dialysis patients. Eur J Med Res 10:161-168
3. Bonventre JV, Force T (1998) Mitogen-activated protein kinases and transcriptional responses in renal injury and repair. Curr Opin Nephrol Hypertens 7:425-433
4. Burnett JC Jr (1999) Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl 17:S37-S43
5. Buschhausen L, Seibold S, Gross O, Matthaeus T, Weber M, Schulze-Lohoff E (2001) Regulation of mesangial cell function by vasodilatory signaling molecules. Cardiovasc Res 51:463-469
6. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE (2001) Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 60:715-721
7. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type 2 diabetes. Kidney Int 57:167-182
8. Floege J, Hackmann B, Kliem V, Kriz W, Alpers CE, Johnson RJ, Kuhn KW, Koch KM (1997) Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int 51:230-243
9. Fredersdorf S, Thumann C, Weil J (2002) Diabetic Cardiomyopathy (DC) is associated with induction of pro-apoptotic proteins and can be reversed by insulin treatment in an animal model of noninsulin dependent diabetes mellitus (NIDDM). Circulation 106 (19):II-1, II-992 (Abstract)
10. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, Kromer EP, Weil J (2004) Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 13:11-19
11. Gades MD, Stern JS, van Goor H, Nguyen D, Johnson PR, Kaysen GA (1998) Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int 53:130-135
12. Gambaro G, D'Angelo A, Del Prete D, Ceol M, Garbisa S, Bertaglia G, Forino M, Baggio B, Anglani F (1999) Mesangial cell proliferation in long-term streptozotocin-induced diabetes mellitus in the rat and the renoprotective activity of heparin. Am J Nephrol 19:530-534
13. Gröne HJ, Walli A, Grone E, Niedmann P, Thiery J, Seidel D, Helmchen U (1989) Induction of glomerulosclerosis by dietary lipids: a functional and morphologic study in the rat. Lab Invest 60:433-446
14. Gross ML, Heiss N, Weckbach M, Hansen A, El-Shakmak A, Szabo A, Munter K, Ritz E, Amann K (2004) ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes. Diabetologia 47:316-324
15. Hiromura K, Haseley LA, Zhang P, Monkawa T, Durvasula R, Petermann AT, Alpers CE, Mundel P, Shankland SJ (2001) Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 60:2235-2246
16. HOPE Study (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355:253-259
17. Kasiske BL, Cleary MP, O'Donnell MP, Keane WF (1985) Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 106:598-604
18. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF (1988) Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672
19. Kasiske BL, O'Donnell MP, Keane WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19:I110-I115
20. Kriz W, Lemley KV (1999) The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8:489-497
21. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui P, Pinel N, Cordonnier DJ, Gilbert RE (2002) Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45:1572-1576
22. Lingohr MK, Buettner R, Rhodes CJ (2002) Pancreatic beta-cell growth and survival - a role in obesity-linked type 2 diabetes? Trends Mol Med 8:375-384
23. Meyer TW, Bennett PH, Nelson RG (1999) Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type 2 diabetes and microalbuminuria. Diabetologia 42:1341-1344
24. Nagata M, Shu Y, Tomari S (2002) Role of cell cycle molecules in the pathophysiology of glomerular epithelial cells. Microsc Res Tech 57:203-207
25. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H (1993) mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42:450-456
26. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, Hess JF (1996) Leptin receptor missense mutation in the fatty Zucker rat (letter). Nat Genet 13:18-19
27. Quaschning T, d'Uscio LV, Shaw S, Luscher TF (2001) Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension 37:1108-1113
28. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982-988
29. Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. Circulation 341:1127-1133
30. Sasaki T, Jyo Y, Tanda N, Kawakami Y, Nohno T, Tamai H, Osawa G (1997) Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy. Kidney Int 51:301-309
31. Schafer S, Linz W, Bube A, Gerl M, Huber J, Kuerzel G, Bleich M, Schmidts HL, Busch AE, Ruetten H (2003a) Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res 60:447-545
32. Schafer S, Linz W, Afkam F (2003b) Treatment of hypertensive nephropathy by the novel vasopeptidase inhibitor AVE7688: nephroprotection beyond ACE inhibition alone. Nephrol Dial Transplant 18(Suppl 4):601
33. Schafer S, Schmidts HL, Bleich M, Busch AE, Linz W (2004a) Nephroprotection in Zucker diabetic fatty rats by vasopeptid inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol 143:27-32
34. Schafer S, Linz W, Vollert H, Biemer-Daub G, Rütten H, Bleich M, Busch AE (2004b) The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephopathy. Diabetologia 47:98-103
35. Schulte EA, Saleh H, Schlatter E (2000) Diadenosine polyphosphates and atrial natriuretic peptide are antiproliferative in rat mesangial cells. Cell Physiol Biochem 10:57-64
36. Sheth T, Parker T, Block A, Hall C, Adam A, Pfeffer MA, Stewart DJ, Qian C, Rouleau JL (2002) Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 90:496-500
37. Sugimoto T, Haneda M, Togawa M, Isono M, Shikano T, Araki S, Nakagawa T, Kashiwagi A, Guan KL, Kikkawa R (1996) Atrial natriuretic peptide induces the expression of MKP-1, a mitogen-activated protein kinase phosphatase, in glomerular mesangial cells. J Biol Chem 271:544-547
38. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, Troy JL, Brenner BM (2001) Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051-2059
39. Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, Kuick RD, Wiggins RC (2005) Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 16:2953-2966
40. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K (1995) llular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935-944